By Developing a Radiomics Model to Predict the Prognosis of Patients With Hepatocellular Carcinoma After Microwave Ablation

Hepatocellular Carcinoma Clinical Trial

Official title:

By Developing a Radiomics Model to Predict the Prognosis of Patients With Hepatocellular Carcinoma After Microwave Ablation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03880721
• Other study ID #: 301jrcsk4
• Status: Recruiting
• Start date: January 1, 2019
• Est. completion date: April 2021

Study information

• Verified date: May 2019
• Source: Chinese PLA General Hospital
• Contact: Jie Yu, Dr
• Phone: 8610-66939530
• Email: yu-jie301[@]hotmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Developing a radiomics model to predict the prognosis of patients with hepatocellular carcinoma after microwave ablation to provide advice for their treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: April 2021
• Est. primary completion date: August 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Patients with primary hepatocellular carcinoma in the department of interventional ultrasound, PLA general hospital, who accept MWA therapy for HCC

Inclusion criteria:

1. Primary hepatocellular

2. No other treatments ware performed before microwave ablation

3. Patient has been clinically diagnosed with HCC definitely, and have a definite operational indication

4. No extrahepatic manifestations and no evidence of vessel invasion and bile duct thrombi

Exclusion Criteria:

• Exclusion criteria:

1. Non-primary hepatocellular carcinoma or hepatic metastases

2. Accept other treatment before microwave ablation

3. Extrahepatic metastasis, vessel invasion or bile duct thrombi

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

Intervention

Procedure:
• Microwave abaltion
Use microwave ablation to treat hepatocellular carcinoma

Locations

Country	Name	City	State
China	Chinese PLA General Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chinese PLA General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUC value	Utilizing area under curve to judge the accurency	through study completion, an average of 2 year
Primary	Sensitivity	diagnosis sensitivity of intelligent ultrasound analysis	through study completion, an average of 2 year
Primary	Specificity	diagnosis specificity of intelligent ultrasound analysis	through study completion, an average of 2 year